A Phase 3 trial with 120 mcg Dexmedetomidine dose to evaluate safety in at-home setting
Latest Information Update: 24 Apr 2024
At a glance
- Drugs Dexmedetomidine (Primary)
- Indications Agitation
- Focus Therapeutic Use
Most Recent Events
- 22 Apr 2024 According to a BioXcel Therapeutics media release, the company announced additional details regarding the planned design of this outpatient trial.the Company expects to enroll approximately 30 patients in a separate study to evaluate the correlation between patient-reported or informant-reported efficacy with trained rater-reported efficacy using Positive and Negative Syndrome Scale-Excitatory Component (PEC) measurements.
- 12 Mar 2024 According to a BioXcel Therapeutics media release, company expects to provide further guidance regarding program plans following receipt of final meeting minutes from FDA.
- 11 Feb 2024 New trial record